Oral THC and CBD after inadequate antiemetic control

2024 | Australia | Randomized phase 2 and 3 trial

Grimison P et al. Journal of Clinical Oncology. 2024;42:4040-4050.

Original publication DOI  |  Study record

Methods: The combined analysis included 147 evaluable adults with chemotherapy-related nausea or vomiting despite guideline-consistent preventive medicines. Oral THC/CBD capsules or placebo were added to antiemetic care during a subsequent chemotherapy cycle.

Findings: Complete response, defined as no vomiting or retching and no rescue medication over 120 hours, occurred in 24% with THC/CBD versus 8% with placebo. Sedation, dizziness, and transient anxiety were more frequent with active treatment.

Limitations: Enrollment fell below the planned 250 participants. The study addressed refractory symptoms with a specific adjunctive formulation. It does not show that cannabis should replace standard antiemetics or that it treats the cancer itself.

Leave a Reply

Your email address will not be published. Required fields are marked *